Correlation Between C677T MTHFR Gene Polymorphism, Plasma Homocysteine Levels and the Incidence of CAD
Tóm tắt
The lesions of coronary atherosclerosis represent the result of a complex, multicellular, inflammatoryhealing response in the coronary arterial wall. In vivo and in vitro cellular and molecular studies have suggested a role for tissue homocysteine in endothelial cell injury and adverse extra-cellular matrix remodeling. Gene polymorphisms in relation with numerous risk factors might increase the incidence of coronary artery disease (CAD). In this review we have focused on the correlations between plasma homocysteine levels, the incidence of cardiovascular disease and the cytosine-to-thymidine substitution at nucleotide 677 (C677T) of the 5, 10-methylenetetrahydrofolate reductase (MTHFR) gene, coding for a key enzyme in methionine-homocysteine metabolism. The role of the C677T MTHFR gene polymorphism in the causation of CAD is controversial. We reviewed 12 recent case-control studies comprising 5370 genotyped patients with CAD and 4961 genotyped participants without CAD. There was no significant difference between those with and without CAD in the frequency of the C677T polymorphism (34.9 vs 33.6%). The frequency of homozygous C677T polymorphism in these groups was 10.9 versus 12.8%, respectively, although there were some ethnic differences in the C677T MTHFR polymorphism. In the analysis of the 12 studies, the odds ratio of CAD associated with the TT genotype (homozygous C677T polymorphism) was 1.18. Only slightly higher plasma homocysteine levels were observed in participants with the val/val (TT) genotype (14.4 ± 2.9 μ.mol/L in TT genotype vs 11.1 ± 1.9 and 11.9 ± 2 μ.mol/L in CC and CT genotype, respectively). In addition, the relation between homocysteine increase after methionine loading and MTHFR genotypes is also controversial. However, hyperhomocysteinemia because of the C677T MTHFR allele may be corrected with oral folic acid therapy. Further investigations on the relationships between MTHFR genotypes and the incidence of CAD should be based on larger samples, paying attention to the differences between various ethnic populations. Individual therapeutic strategies based on single nucleotide polymorphism may become increasingly important for preventive treatment against polygenic CAD.
Tài liệu tham khảo
National Centre for Health Statistics. Vital Statistics of the United States, 1993. Washington, DC: US Government Printing Office, Public Health Service, 1993: II (Pt A)
Kannel WB. The Framingham Study: its 50-year old legacy and future promise. J Atheroscler Thromb 2000; 6: 60–6
Ross R. The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 1993; 362: 801–9
Lusis AJ. Atherosclerosis. Nature 2000; 407: 233–41
Dahlof B, Lindholm LH, Hansson L, et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991; 338: 1281–5
O’Connor NJ, Manson JE, O’Connor GT, et al. Psychosocial risk factors and nonfatal myocardial infarction. Circulation 1995; 92: 1458–64
Schaefer EJ, Lamon-Fava S, Jenner JL, et al. Lipoprotein(a) levels and risk of coronary heart disease in men: The Lipid Research Clinics Coronary Primary Prevention Trial. JAMA 1994; 271: 999–1003
Barrett-Connor EL, Bush TL. Estrogen and coronary heart disease in women. JAMA 1991; 265: 1861–7
Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301–7
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9
Rutan GH, Kuller LH, Neaton JD. Mortality associated with diastolic hypertension and isolated systolic hypertension among men screened for the Multiple Risk Factor Intervention Trial(MRFIT). Circulation 1988; 77: 504–14
du Vigneaud V, Ressler C, Rachele JR. The biological synthesis of labile methyl groups. Science 1959; 112: 267–71
Finkelstein JD. Methionine metabolism in mammals. J Nutr Biochem 1990; 1: 228–37
Mayer EM, Jacobsen DW, Robinson K. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol 1996; 27: 517–27
Malinow MR, Axthelm MK, Meredith MJ, et al. Synthesis and transsulfuration of homocysteine in blood. J Lab Clin Med 1994; 123: 421–29
Mudd SH, Levy HL, Skovby F. Disorders of transsulfuration. In: Scriver CR, Beaudet AL, Sly WS, et al., editors. The metabolic basis of inherited disease. 6th ed. New York: McGraw Hill, 1989: 693–734
Shaw JT, McWhinney B, Tate JR, et al. Plasma homocysteine levels in indigenous Australians. Med J Aust 1999; 170: 19–22
Tyagi SC. Homocyct(e)ine and heart disease: pathophysiology of extracellular matrix. Clin Exp Hypertens 1999; 21: 181–98
Tsai JC, Perrella MA, Yoshizumi M, et al. Promotion of vascular smooth muscle cell growth by homocysteine: A link to atherosclerosis. Proc Natl Acad Sci US A 1994; 91: 6369–73
Welch GN, Loscalzo J. Hyperhomocyst(e)inemia and atherothrombosis. N Engl J Med 1998; 338: 1042–50
Kang SS, Wong PWK, Susmano A, et al. Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for coronary artery disease. Am J Hum Genet 1991; 48:536–45
Goyette P, Sumner JS, Milos R, et al. Human methylenetetrahydrofolate reductase: isolation of cDNA, mapping and mutation identification. Nat Genet 1994; 7: 195–200
Goyette P, Frosst P, Rosenblatt D S, et al. Seven novel mutations in the methylenetetrahydrofolate reductase gene and genotype/phenotype correlations in severe methylenetetra- hydrofolate reductase deficiency. Am J Hum Genet 1995; 56: 1052–59
Goyette P, Pai A, Milos R, et al. Gene structure of human and mouse methylenetetrahydrofolate reductase (MTHFR). Mamm Genome 1998; 9: 652–6
Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10:111–3
Kluijtmans LAJ, van den Heuvel LPWJ, Boers GHJ, et al. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet 1996; 58: 35–41
Adams M, Smith PD, Martin D, et al. Genetic analysis of thermolabile methylenetetrahydrofolate reductase as a risk factor for myocardial infarction. Q J Med 1996; 89: 437–44
Morita H, Taguchi J, Kurihara, H, et al. Genetic polymorphism of 5, 10-methylenetetrahydrofolate reductase (MTHFR) as a risk factor for coronary artery disease. Circulation 1997; 95: 2032–6
Nakai K, Fusazaki T, Suzuki T, et al. Genetic polymorphism of 5, 10-methylenetetrahydrofolate increases risk of myocardial infarction and is correlated to elevated levels of homocysteine in the Japanese general population. Coron Artery Dis 2000; 11:47–51
van Bockxmeer FM, Mamotte CDS, Vasikaran SD, et al. Methylenetetrahydrofolate reductase gene and coronary artery disease. Circulation 1997; 95: 21–3
Schwartz SM, Siscovick DS, Malinow MR, et al. Myocardial infarction in young women in relation to plasma total homocysteine, folate, and a common variant in the methylenetetrahydrofolate reductase gene. Circulation 1997; 96: 412–7
Brattstrom L. Wilcken DE. Ohrvik J, et al. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the result of a meta-analysis. Circulation 1998; 98: 2520–6
Ma J, Stampfer MJ, Hennekens CH, et al. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians. Circulation 1996; 94: 2410–6
Izumi M, Iwai N, Ohmichi N, et al. Molecular variant of 5, 10-methylenetetrahydrofolate reductase is a risk factor of ischemic heart disease in the Japanese population [letter]. Atherosclerosis 1996; 121: 293–4
Wilcken DE, Wang XL, Sim AS, et al. Distribution in healthy and coronary populations of the methylenetetrahydrofolate reductase (MTHFR) C677T mutation. Arterioscler Thromb Vasc Biol 1996; 16: 878–2
Kluijtmans LA, Kastelein JJ, Lindemans J, et al. Thermolabile methylenetetrahydrofolate reductase in coronary artery disease. Circulation. 1997; 96: 2573–7
Anderson JL, King GJ, Thomson MJ, et al. A mutation in the methylenetetrahydrofolate reductase gene is not associated with increased risk for coronary artery disease or myocardial infarction. J Am Coll Cardiol 1997; 30: 1206–1
Reinhardt D, Sigusch H, Hvogt SF, et al. Absence of association between a common mutation in the methylenetetrahydrofolate reductase gene and the risk of coronary artery disease. Eur J Clin Invest 1998; 28: 20–3
Girelli D, Friso S, Trabetti E, et al. Methylenetetrahydrofolate reductase C677T mutation, plasma homocysteine, and folate in individuals from northern Italy with or without angiographically documented severe coronary atherosclerotic disease: evidence for an important genetic-environmental interaction. Blood 1998; 91: 4158–63
Verhoeff BJ, Trip MD, Prins MH, et al. The effect of a common methylenetetrahydrofolate reductase mutation on levelsof homocysteine, folate, vitamin B12 and on the risk of premature atherosclerosis. Atherosclerosis 1998; 141: 161–6
Gardemann A, Weidemann H, Philipp M, et al. The TT genotype of the methylenetetrahydrofolate reductase C677T gene polymorphism is associated with the extent of coronary atherosclerosis in patients at high risk for coronary artery disease. Eur Heart J 1999; 20: 584–92
McAndrew PE, Brandt JT, Pearl DK, et al. The incidence of the gene for thermolabile methylene tetrahydrofolate reductase in African Americans. Thromb Res 1996; 83: 195–8
National Laboratory for the Genetics of Israeli Populations. Available from URL: http://www.tau.ac.il/medicine/NLGIP/nlgip.htm. [Accessed 2001 Aug 31]
Ravnskov U. The questionable role of saturated and polyunsaturated fatty acids in cardiovascular disease. J Clin Epidemiol 1998; 51: 443–60
Pollak RD, Friedlander Y, Pollak A, et al. Ethnic differences in the frequency of the C677T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene in healthy Israeli populations. Genet Test 2000; 4: 309–11
Fletcher O, Kessling AM. MTHFR association with arteriosclerotic vascular disease? Hum Genet 1998; 103: 11–21
Christensen B, Frosst P, Lussier-Cacan S, et al. Correlation of a common mutation in the methylenetetrahydrofolate reductase gene with plasma homocysteine in patients with premature coronary artery disease. Arterioscler Thromb Vasc Biol 1997; 17: 569–73
Verhoef P, Kok FJ, Kluijtmans LAJ, et al. The 677C-T mutation in the methylenetetrahydrofolate reductase gene: association with plasma total homoccteine levels and risk of coronary atherosclerotic disease. Atherosclerosis 1997; 132: 105–13
Tsai MY, Welge BG, Hanson NQ, et al. Genetic causes of mild hyperhomocysteinemia in patients with premature occlusive coronary artery disease. Atherosclerosis 1999; 143: 163–70
Chao CL, Tsai HH, Lee CM, et al. The graded effect of hyperhomocysteinemia on the severity and extent of coronary atherosclerosis. Atherosclerosis 1999; 147: 379–80
Anderson JL, Muhlestein JB, Horne BD, et al. Plasma homocysteine predicts mortality undependently of traditional risk factors and C-reactive protein in patients with angiographically defined coronary artery disease. Circulation 2000; 102: 1227–32
Mudd SH, Levy HL, Skovby F, et al. The metabolic basis of inherited disease. 6th ed. New York: McGraw Hill, 1989: 693–734
Boushey CJ, Beresford SA, Omenn GC, et al. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995; 274: 1049–57
Guttormsen AB, Ueland PM, Nesthus I, et al. Determinants and vitamin responsiveness of intermediate hyper- homocysteinemia (equal to or greater than 40 micromole/liter): the Hordaland homocysteine study. J Clin Invest 1996; 98: 2174–83